LTR Pharma enters deal with Mens Health Downunder to supply Spontan. Pic via Getty Images.
Health & Biotech
Special Report: LTR Pharma has inked an access agreement with Mens Health Downunder to facilitate supply of Spontan, ,its novel nasal spray treatment for erectile dysfunction through the Therapeutic Goods Administration’s Special Access Scheme.
Mens Health Downunder (MHDU) specialises in comprehensive men’s urological healthcare solutions and currently services more than 1000 patients annually.
LTR Pharma (ASX:LTP) said the agreement provided the company with access to MHDU’s extensive referral network, which includes pharmacists, general practitioners, urologists, nurses and sexual health clinics across multiple locations in Australia.
The company said the first patient had received Spontan treatment through the health provider’s pharmacy network.
The company’s lead asset SPONTAN is set apart from existing erectile dysfunction therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor.
LTR Pharma said the nasal cavity was a highly vascular part of the body supporting even and rapid absorption of the drug.
Results of a pivotal trial showed a 470% faster absorption than oral vardenafil of 12 minutes versus 56 minutes.
The company emphasised its favourable safety profile positions Spontan as a disruptor in the global erectile dysfunction market.
LTR Pharma said the agreement with MHDU aligned with its strategy to introduce SPONTAN through trusted healthcare providers while gathering valuable real-world patient data.
The agreement builds upon LTR Pharma’s recent achievements in establishing early access to Spontan through the TGA’s Special Access Scheme (SAS) and Authorised Prescriber Scheme (APS).
LTR Pharma announced in August the first group of patients received Spontan under the APS.
Unlike the case-by-case approach of the SAS, the company noted the APS allowed registered medical practitioners to prescribe Spontan to a broader class of patients with erectile dysfunction, streamlining access for those who may benefit.
LTR Pharma said the agreement provides it with the benefit of MHDU’s established presence in key Australian markets, adding that MHDU’s comprehensive consultation approach aligns with its commitment to improving outcomes in men’s health.
The organisations are collaborating on initial packaging solutions designed for pharmacy availability of Spontan with the development work representing an important step in preparing the erectile dysfunction treatment for broader market access, anticipated in early 2025.
LTR Pharma said packaging requirements for the TGA’s SAS and APS differed from the packaging slated for full commercial launch following TGA approval.
The partnership with MHDU aims to provide valuable insights into pharmacy and patient needs, which will inform the development of commercial packaging ahead of the full market launch.
MHDU founder and executive chairman Brad Butt said the collaboration with LTR Pharma enhances its ability to provide innovative solutions for men’s health concerns.
“Spontan’s rapid-onset profile addresses a significant unmet need in erectile dysfunction treatment, complementing our multi-disciplinary and multi-modal approach to men’s healthcare,” he said.
LTR Pharma chairman Lee Rodne said the agreement with MHDU represented another significant milestone in Spontan’s commercialisation journey.
“By partnering with Australia’s largest men’s health pharmacy clinic, we continue to broaden access to Spontan while maintaining our commitment to patient care through qualified healthcare professionals,” he said.
This article was developed in collaboration with LTR Pharma, a Stockhead advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Health & Biotech
Health & Biotech
Health & Biotech
